Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer.
Hyun Cheol ChungVictor C KokRebecca ChengYanzhi HsuMauro OrlandoCharles FuchsJae Yong ChoPublished in: Asia-Pacific journal of clinical oncology (2018)
Despite limitations, this subgroup analysis suggests that ramucirumab monotherapy improves efficacy outcomes with a tolerable safety profile in EA patients with previously treated advanced gastric cancer.
Keyphrases
- phase iii
- open label
- clinical trial
- phase ii
- newly diagnosed
- end stage renal disease
- double blind
- neoadjuvant chemotherapy
- placebo controlled
- healthcare
- peritoneal dialysis
- palliative care
- prognostic factors
- study protocol
- squamous cell carcinoma
- health insurance
- patient reported outcomes
- chronic pain
- combination therapy
- metabolic syndrome
- insulin resistance
- patient reported
- affordable care act